Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611hxl

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	DEC 08	INPADOC: Legal Status data reloaded
NEWS 5	SEP 29	DISSABS now available on STN
NEWS 6	OCT 10	PCTFULL: Two new display fields added
NEWS 7	OCT 21	BIOSIS file reloaded and enhanced
NEWS 8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9	NOV 24	MSDS-CCOHS file reloaded
NEWS 10	DEC 08	CABA reloaded with left truncation
NEWS 11	DEC 08	IMS file names changed
NEWS 12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 14	DEC 17	DGENE: Two new display fields added
NEWS 15	DEC 18	BIOTECHNO no longer updated
NEWS 16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS 17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS 18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19	DEC 22	ABI-INFORM now available on STN
NEWS 20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 22	FEB 05	German (DE) application and patent publication number format changes
NEWS 23	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 24	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 25	MAR 03	FRANCEPAT now available on STN
NEWS 26	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS 27	MAR 29	WPIFV now available on STN
NEWS 28	MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS 29	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA

NEWS EXPRESS	MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:13:15 ON 29 MAR 2004

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:13:25 ON 29 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAR 2004 HIGHEST RN 668418-93-7
DICTIONARY FILE UPDATES: 28 MAR 2004 HIGHEST RN 668418-93-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10089953.str



chain nodes :
26 27 28 29 30 31 32 33 38
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25
ring/chain nodes :
39
chain bonds :
13-28 17-38 19-27 20-33 26-27 27-29 28-29 29-30 30-31 31-32 31-33 38-39
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-16 5-6 5-19 7-8 7-12 8-9 9-10 10-11 10-13 11-12
11-15 13-14 14-15 16-17 17-18 18-19 20-21 20-25 21-22 22-23 23-24 24-25

exact/norm bonds :
4-16 5-19 10-13 11-15 13-14 13-28 14-15 16-17 17-18 17-38 18-19 19-27
20-21 20-25 20-33 21-22 22-23 23-24 24-25 26-27 27-29 28-29 29-30 30-31
31-32 31-33 38-39
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS 28:CLASS
29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 38:CLASS 39:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 15:13:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 502 TO ITERATE

100.0% PROCESSED 502 ITERATIONS 344 ANSWERS
SEARCH TIME: 00.00.01

L2 344 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 155.42 155.63

FILE 'CAPLUS' ENTERED AT 15:14:01 ON 29 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 29 Mar 2004 VOL 140 ISS 14
FILE LAST UPDATED: 28 Mar 2004 (20040328/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 3 L2

=> d abs ibib hitstr 1-
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I

AB The title compds. represented by the formula (I) (wherein X and X1 are the same or different and each represents H, halo, or (un)substituted NH2; R1 and R2 are the same or different and each represents H or (un)substituted C1-6 alkyl; or NR1R2 forms (un)substituted N-containing heterocyclic ring; R3 represents an each optionally substituted hydrocarbon group or heterocyclyl; R4 represents H or an each optionally substituted hydrocarbon group or heterocyclyl; Y and Ya are the same or different and each represents a bond or a spacer having a C1-8 main chain; and Z and Za are the same or different and each represents H, halo, or (un)substituted cyclic group), salts of the compds., or prodrugs of either are prepared They have inhibitory activity against somatostatin receptor, in particular somatostatin receptor subtype 2 binding and are agonists of somatostatin receptor and effective in the prevention of and treatment for diseases in which somatostatin participates, in particular diabetes or diabetes complications. Thus, a solution of 2.6 g (2RS,3SR)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-3-(1H-indol-3-yl)butanoic acid and 0.06 mL DMF in 60 mL THF was treated dropwise with a solution of 0.63 mL oxalyl chloride in 5 mL THF at 0°, stirred at 0° for 30 min, concentrated, treated with 30 mL THF, and reconcd., dissolved in 30 mL THF, added dropwise at 0° to a solution of 1-[(3S)-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl]-N,N-dimethylmethaneamine 0.90 g, tetrabutylammonium hydrogen sulfate 0.04 g, and NaOH powder 0.34 g, stirred at 0° for 30 min to give, after workup and silica gel chromatog., a yellow amorphous solid which was stirred with 0.2 mL piperidine in 20 mL methanol at room temperature for 16 h to give, after alumina chromatog., 49% (2RS,3SR)-1-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-3-(1H-indol-3-yl)-1-oxo-2-butanamine (II; R = H). WSC (0.10 g) was added to a solution of II 0.20, 1-[(1-methyl-1H-indol-2-yl)carbonyl]-4-piperidinecarboxylic acid 0.15 g, and HOBt 0.08 g in 10 mL MeCN, stirred at room temperature for 16 h to give, after workup and silica gel chromatog., 64% II (R = Q). II (R = Q1) in vitro inhibited the binding of 125I-somatostatin-14 to human somatostatin receptor protein subtype 2, 3, and 5 with showed IC50 of 0.05, 3, and 10, resp. A tablet formulation containing II (R = H) was described.

ACCESSION NUMBER: 2003:396877 CAPLUS
DOCUMENT NUMBER: 138:401769
TITLE: Preparation of [1-[3-(indol-3-yl)propanoyl]-1,2,3,4-tetrahydroquinolin-3-ylmethyl]amine derivatives as somatostatin receptor binding inhibitors

INVENTOR(S): Abe, Hidenori; Kasai, Shizuo; Takekawa, Shiro; Watanabe, Masanori
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 191 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003042204	A1	20030522	WO 2002-JP10800	20021017

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

JP 2003192682	A2	20030709	JP 2002-303222	20021017

PRIORITY APPLN. INFO.: JP 2001-322897 A 20011019
OTHER SOURCE(S): MARPAT 138:401769
IT **528857-60-5P 528857-61-6P 528857-62-7P**
528857-63-8P 528857-69-4P 528857-75-2P
528857-95-6P 528857-97-8P 528857-99-0P
528858-01-7P 528858-07-3P 528858-23-3P
528858-24-4P 528858-25-5P 528858-26-6P
528858-27-7P 528858-31-3P 528858-35-7P
528858-65-3P 528858-67-5P 528858-75-5P
528859-03-2P 528859-24-7P 528859-34-9P
528859-47-4P 528859-53-2P 528859-57-6P
528859-60-1P 528859-63-4P 528859-66-7P
528859-70-3P 528859-74-7P 528859-77-0P
528859-80-5P 528859-83-8P 528859-86-1P
528859-89-4P 528859-92-9P 528859-95-2P
528859-98-5P 528860-01-7P 528860-04-0P
528860-07-3P 528860-10-8P 528860-13-1P
528860-19-7P 528860-22-2P 528860-25-5P
528860-28-8P 528860-31-3P 528860-34-6P
528860-37-9P 528860-40-4P 528860-43-7P
528860-46-0P 528860-49-3P 528860-52-8P
528860-55-1P 528860-57-3P 528860-60-8P
528860-62-0P 528860-64-2P 528860-66-4P
528861-05-4P 528861-06-5P 528861-07-6P
528861-08-7P 528861-09-8P 528861-10-1P
528861-11-2P 528861-12-3P 528861-13-4P
528861-14-5P 528861-15-6P 528861-16-7P
528861-17-8P 528861-18-9P 528861-19-0P
528861-20-3P 528861-21-4P 528861-22-5P
528861-23-6P 528861-24-7P 528861-25-8P
528861-26-9P 528861-27-0P 528861-28-1P
528861-29-2P 528861-30-5P 528861-31-6P
528861-32-7P 528893-11-0P 528893-13-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of [[(indolylpropanoyl)tetrahydroquinolinyl]methyl]amine derivs. as somatostatin receptor binding inhibitors (agonists) for prevention or treatment of diabetes or diabetes complications)

RN 528857-60-5 CAPLUS
CN 4-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-1-[(1-methyl-1H-indol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528857-61-6 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-1-[(1-methyl-1H-indol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528857-62-7 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1S,2R)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-1-[(1-methyl-1H-indol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528857-63-8 CAPLUS
CN 4-Piperidinecarboxamide, N-[1-[[(3S)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-1-[(1-methyl-1H-indol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528857-69-4 CAPLUS
CN Benzeneacetamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-α-hydroxy-, (αS)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 528857-68-3
CMF C32 H35 Cl N4 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528857-75-2 CAPLUS
CN Benzamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-methoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528857-74-1
CMF C32 H35 Cl N4 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528857-95-6 CAPLUS
CN Benzamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-2-fluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528857-94-5
CMF C31 H32 Cl F N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528857-97-8 CAPLUS
CN Benzamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-2,6-difluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528857-96-7
CMF C31 H31 Cl F2 N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528857-99-0 CAPLUS
CN Benzamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-3-fluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528857-98-9
CMF C31 H32 Cl F N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528858-01-7 CAPLUS
CN Benzamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-2,4-difluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528858-00-6
CMF C31 H31 Cl F2 N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528858-07-3 CAPLUS
CN 4-Piperidinecarboxamide, 1-acetyl-N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528858-06-2
CMF C32 H40 Cl N5 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528858-23-3 CAPLUS
CN Cyclohexanecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528858-22-2
CMF C31 H39 Cl N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528858-24-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-phenoxy-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528858-25-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528858-26-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1S,2R)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528858-27-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3S)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528858-31-3 CAPLUS
CN 3-Quinolinemethanamine, 6-chloro-1-[2-[[[(cyclohexylmethyl)amino]carbonyl]amino]-3-(1H-indol-3-yl)-1-oxobutyl]-1,2,3,4-tetrahydro-N,N-dimethyl-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528858-30-2
CMF C32 H42 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528858-35-7 CAPLUS
CN 3-Quinolinemethanamine, 6-chloro-1,2,3,4-tetrahydro-1-[3-(1H-indol-3-yl)-1-oxo-2-[[[(phenylmethyl)amino]carbonyl]amino]butyl]-N,N-dimethyl-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528858-34-6
CMF C32 H36 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528858-65-3 CAPLUS
CN 2(1H)-Isoquinolinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-3,4-dihydro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528858-64-2
CMF C34 H38 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528858-67-5 CAPLUS
CN 1,4-Piperidinedicarboxamide, N1-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528858-66-4
CMF C31 H39 Cl N6 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528858-75-5 CAPLUS
CN 3-Quinolinemethanamine, 6-chloro-1,2,3,4-tetrahydro-1-[3-(1H-indol-3-yl)-2-[[[methyl(phenylmethyl)amino]carbonyl]amino]-1-oxobutyl]-N,N-dimethyl-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528858-74-4
CMF C33 H38 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528859-03-2 CAPLUS
CN 3-Quinolinemethanamine, 6-chloro-1,2,3,4-tetrahydro-1-[3-(1H-indol-3-yl)-1-oxo-2-[[[[2-(1-piperidinyl)ethyl]amino]carbonyl]amino]butyl]-N,N-dimethyl-, (3R)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-02-1
CMF C32 H43 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528859-24-7 CAPLUS
CN 3-Quinolinemethanamine, 6-chloro-1,2,3,4-tetrahydro-1-[3-(1H-indol-3-yl)-1-oxo-2-[[[(4-pyridinylmethyl)amino]carbonyl]amino]butyl]-N,N-dimethyl-, (3R)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-23-6
CMF C31 H35 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528859-34-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-ethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-33-8
CMF C31 H41 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528859-47-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(1-pyrrolidinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-46-3
CMF C34 H45 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528859-53-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-52-1
CMF C36 H40 Cl F3 N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528859-57-6 CAPLUS
CN 1-Piperazinecarboxamide, 4-(4-acetylphenyl)-N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-56-5
CMF C37 H43 Cl N6 O3

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528859-60-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(2-chlorophenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-59-8
CMF C35 H40 Cl2 N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528859-63-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(3-methoxyphenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-62-3
CMF C36 H43 Cl N6 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528859-66-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(3-chlorophenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-65-6
CMF C35 H40 Cl2 N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528859-70-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(2-methylphenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-69-0
CMF C36 H43 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528859-74-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(2-ethoxyphenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-73-6
CMF C37 H45 Cl N6 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528859-77-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(2-fluorophenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-76-9
CMF C35 H40 Cl F N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528859-80-5 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-chlorophenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-79-2
CMF C35 H40 Cl2 N6 O2

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528859-83-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-methoxyphenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-82-7
CMF C36 H43 Cl N6 O3

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528859-86-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-fluorophenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-85-0
CMF C35 H40 Cl F N6 O2

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528859-89-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(3-methylphenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-88-3
CMF C36 H43 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528859-92-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(phenylmethyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-91-8
CMF C36 H43 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528859-95-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-94-1
CMF C34 H40 Cl N7 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528859-98-5 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-phenyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-97-4
CMF C35 H41 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-01-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(2-methoxyphenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-00-6
CMF C36 H43 Cl N6 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-04-0 CAPLUS
CN [1,4'-Bipiperidine]-1'-carboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-03-9
CMF C35 H47 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-07-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(2-pyrimidinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-06-2
CMF C33 H39 Cl N8 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-10-8 CAPLUS
CN 3-Quinolinemethanamine, 6-chloro-1,2,3,4-tetrahydro-1-[3-(1H-indol-3-yl)-1-oxo-2-[[[[4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]amino]butyl]-N,N-dimethyl-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-09-5
CMF C33 H35 Cl F3 N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-13-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-12-0
CMF C37 H44 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-19-7 CAPLUS
CN 3-Quinolinemethanamine, 6-chloro-1-[2-[[[(4-fluorophenyl)amino]carbonyl]amino]-3-(1H-indol-3-yl)-1-oxobutyl]-1,2,3,4-tetrahydro-N,N-dimethyl-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-18-6
CMF C31 H33 Cl F N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-22-2 CAPLUS
CN 3-Quinolinemethanamine, 6-chloro-1-[2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-(1H-indol-3-yl)-1-oxobutyl]-1,2,3,4-tetrahydro-N,N-dimethyl-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-21-1
CMF C31 H33 Cl2 N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-25-5 CAPLUS
CN 3-Quinolinemethanamine, 6-chloro-1-[2-[[[(2,3-dihydro-1H-inden-5-yl)amino]carbonyl]amino]-3-(1H-indol-3-yl)-1-oxobutyl]-1,2,3,4-tetrahydro-N,N-dimethyl-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-24-4
CMF C34 H38 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-28-8 CAPLUS
CN Benzamide, 4-[[[[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]amino]carbonyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-27-7
CMF C32 H35 Cl N6 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-31-3 CAPLUS
CN 3-Quinolinemethanamine, 6-chloro-1-[2-[[[[4-(dimethylamino)phenyl]amino]carbonyl]amino]-3-(1H-indol-3-yl)-1-oxobutyl]-1,2,3,4-tetrahydro-N,N-dimethyl-, (3R)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-30-2
CMF C33 H39 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-34-6 CAPLUS
CN 3-Quinolinemethanamine, 6-chloro-1-[2-[[[(2-ethoxyphenyl)amino]carbonyl]amino]-3-(1H-indol-3-yl)-1-oxobutyl]-1,2,3,4-tetrahydro-N,N-dimethyl-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-33-5
CMF C33 H38 Cl N5 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-37-9 CAPLUS
CN 3-Quinolinemethanamine, 6-chloro-1,2,3,4-tetrahydro-1-[3-(1H-indol-3-yl)-2-[[[[3-(methylthio)phenyl]amino]carbonyl]amino]-1-oxobutyl]-N,N-dimethyl-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-36-8
CMF C32 H36 Cl N5 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-40-4 CAPLUS
CN 3-Quinolinemethanamine, 6-chloro-1-[2-[[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]-3-(1H-indol-3-yl)-1-oxobutyl]-1,2,3,4-tetrahydro-N,N-dimethyl-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-39-1
CMF C35 H42 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-43-7 CAPLUS
CN Acetamide, N-[4-[[[[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]amino]carbonyl]amino]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-42-6
CMF C33 H37 Cl N6 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-46-0 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-45-9
CMF C36 H42 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-49-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(3-fluorophenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-48-2
CMF C36 H41 Cl F N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-52-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-fluorophenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-51-7
CMF C36 H41 Cl F N5 O2

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-55-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(2-methylphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-54-0
CMF C37 H44 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-57-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(3-methylphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-56-2
CMF C37 H44 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-60-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-methylphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-59-5
CMF C37 H44 Cl N5 O2

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-62-0 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(3-methoxyphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-61-9
CMF C37 H44 Cl N5 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-64-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-chlorophenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-63-1
CMF C36 H41 Cl2 N5 O2

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528860-66-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-benzoyl-N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528860-65-3
CMF C37 H42 Cl N5 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528861-05-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-hydroxyphenoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-06-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-cyanophenoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-07-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-

3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-methoxyphenoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-08-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(3-hydroxyphenoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-09-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-[4-(1H-tetrazol-5-yl)phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-10-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-chlorophenoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-11-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-methylphenoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-12-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-

3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-13-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(3-methylphenoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-14-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-15-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-[4-(aminosulfonyl)phenoxy]-N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 528861-16-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-17-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(3-methylphenoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-18-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-

[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-19-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-20-3 CAPLUS
CN 1-Piperazinecarboxamide, 4-benzoyl-N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-21-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-benzoyl-N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-22-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-

[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-23-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-chlorophenoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-24-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-methylphenoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-25-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-[4-(methylsulfonyl)phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 528861-26-9 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-27-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-28-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-

[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(3-fluorobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-29-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(2-fluorobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-30-5 CAPLUS
CN 1-Piperazinecarboxamide, 4-(4-chlorobenzoyl)-N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-31-6 CAPLUS
CN 1-Piperazinecarboxamide, 4-(3-chlorobenzoyl)-N-[(1R,2S)-1-[[(3R)-6-chloro-

3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528861-32-7 CAPLUS
CN 1-Piperazinecarboxamide, 4-(2-chlorobenzoyl)-N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528893-11-0 CAPLUS
CN 2(1H)-Isoquinolinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]octahydro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528893-10-9
CMF C34 H44 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 528893-13-2 CAPLUS
CN 1,3-Piperidinedicarboxamide, N1-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528893-12-1
CMF C31 H39 Cl N6 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I

AB The title compds. I [X and X' are the same or different and each represents hydrogen, fluorine, etc., provided that at least one of X and X' represents fluorine, chlorine, etc.; R1 and R2 represents each hydrogen or optionally substituted C1-6 alkyl, or R1 and R2 form together with the nitrogen atom adjacent thereto an optionally substituted nitrogen-containing heterocycle; Y and Q are the same or different and each represents a bond or a spacer having 1 to 6 atoms in the main chain; the dotted line represents a single or double bond; T1 and T2 represent each C(R9) (wherein R9 represents hydrogen, hydroxy, etc.), N, etc.; and Ar represents an optionally substituted aromatic group, hydrogen, etc.; a provision is given] are prepared In an in vitro test for inhibition of binding to the somatostatin receptor type 2, several compds. of this invention showed IC50 of 0.6 to 2 nM. Formulations are given.

ACCESSION NUMBER: 2001:265411 CAPLUS
DOCUMENT NUMBER: 134:295840
TITLE: Preparation of indolylpropanoyltetrahydroquinoline derivatives which inhibit binding of somatostatin receptors
INVENTOR(S): Kato, Kaneyoshi; Terauchi, Jun; Suzuki, Nobuhiro; Takekawa, Shiro
PATENT ASSIGNEE(S): Tadeka Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025228	A1	20010412	WO 2000-JP6937	20001005

W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2000075568	A5	20010510	AU 2000-75568	20001005
JP 2002088079	A2	20020327	JP 2000-311723	20001005
EP 1227090	A1	20020731	EP 2000-964676	20001005

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL

PRIORITY APPLN. INFO.:	JP 1999-286939	A	19991007
	JP 2000-215837	A	20000711
	WO 2000-JP6937	W	20001005

OTHER SOURCE(S): MARPAT 134:295840

IT **333952-68-4P 333952-69-5P 333952-70-8P**
333952-71-9P 333952-72-0P 333952-73-1P
333952-74-2P 333952-75-3P 333952-76-4P
333952-77-5P 333952-78-6P 333952-79-7P
333952-80-0P 333952-81-1P 333952-82-2P
333952-83-3P 333952-84-4P 333952-85-5P
333952-86-6P 333952-87-7P 333952-88-8P
333952-89-9P 333952-90-2P 333952-91-3P
333952-92-4P 333952-93-5P 333952-94-6P
333952-95-7P 333952-96-8P 333952-97-9P
333952-98-0P 333952-99-1P 333953-00-7P
333953-01-8P 333953-02-9P 333953-03-0P
333953-04-1P 333953-05-2P 333953-06-3P
333953-07-4P 333953-08-5P 333953-09-6P
333953-10-9P 333953-11-0P 333953-12-1P
333953-13-2P 333953-14-3P 333953-15-4P
333953-16-5P 333953-17-6P 333953-18-7P
333953-19-8P 333953-20-1P 333953-21-2P
333953-22-3P 333953-23-4P 333953-24-5P
333953-25-6P 333953-26-7P 333953-27-8P
333953-28-9P 333953-29-0P 333953-30-3P
333953-31-4P 333953-32-5P 333953-33-6P
333953-34-7P 333953-35-8P 333953-36-9P
333953-37-0P 333953-38-1P 333953-39-2P
333953-40-5P 333953-41-6P 333953-42-7P
333953-43-8P 333953-44-9P 333953-45-0P
333953-46-1P 333953-47-2P 333953-48-3P
333953-49-4P 333953-50-7P 333953-51-8P
333953-52-9P 333953-53-0P 333953-54-1P
333953-55-2P 333953-56-3P 333953-57-4P
333953-58-5P 333953-59-6P 333953-60-9P
333953-61-0P 333953-62-1P 333953-63-2P
333953-64-3P 333953-65-4P 333953-66-5P
333953-67-6P 333953-68-7P 333953-69-8P
333953-70-1P 333953-71-2P 333953-72-3P
333953-73-4P 333953-74-5P 333953-75-6P
333953-76-7P 333953-77-8P 333953-78-9P
333953-79-0P 333953-80-3P 333953-81-4P
333953-82-5P 333953-83-6P 333953-84-7P
333953-85-8P 333953-86-9P 333953-87-0P
333953-88-1P 333953-89-2P 333953-90-5P
333953-91-6P 333953-92-7P 333953-93-8P
333953-94-9P 333953-95-0P 333953-96-1P
333953-97-2P 333953-98-3P 333953-99-4P
333954-00-0P 333954-01-1P 333954-02-2P
333954-03-3P 333954-04-4P 333954-05-5P
333954-06-6P 333954-07-7P 333954-08-8P
333954-09-9P 333954-10-2P 333954-11-3P
333954-12-4P 333954-13-5P 333954-14-6P

333954-15-7P 333954-16-8P 333954-17-9P
333954-18-0P 333954-19-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolylpropanoyltetrahydroquinoline derivs. which inhibit binding of somatostatin receptors)

RN 333952-68-4 CAPLUS
CN 4-Piperidinecarboxamide, 1-benzoyl-N-[(1R)-2-[3-[(dimethylamino)methyl]-6-fluoro-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-69-5 CAPLUS
CN 4-Piperidinepropanamide, 1-benzoyl-N-[(1R)-2-[5-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-70-8 CAPLUS
CN 4-Piperidinecarboxamide, 1-benzoyl-N-[(1R)-2-[(3S)-5-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-71-9 CAPLUS
CN 4-Piperidinepropanamide, 1-benzoyl-N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-72-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-73-1 CAPLUS
CN 4-Piperidineacetamide, 1-benzoyl-N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-74-2 CAPLUS
CN 4-Piperidinecarboxamide, 1-benzoyl-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-75-3 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-76-4 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(2-methylbenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-77-5 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(2-methoxybenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-78-6 CAPLUS
CN 4-Piperidinecarboxamide, 1-(2-chlorobenzoyl)-N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-79-7 CAPLUS
CN 4-Piperidinecarboxamide, 1-(benzo[b]thien-2-ylcarbonyl)-N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-80-0 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(phenylacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-81-1 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(1H-indol-2-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-82-2 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(1H-indol-3-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-83-3 CAPLUS
CN 4-Piperidinecarboxamide, 1-(2-benzofuranylcarbonyl)-N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-84-4 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(2-thienylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-85-5 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(3-thienylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-86-6 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-87-7 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[(4-chlorophenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-88-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[5-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-89-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-6-fluoro-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-90-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R)-2-[3-[(dimethylamino)methyl]-6-fluoro-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-91-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)-N-[(1R)-2-[3-[(dimethylamino)methyl]-6-fluoro-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-92-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[5-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-93-5 CAPLUS
CN 4-Piperidinecarboxamide, 1-benzoyl-N-[(1R)-2-[5-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-94-6 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-95-7 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-96-8 CAPLUS
CN 4-Piperidinecarboxamide, 1-acetyl-N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-97-9 CAPLUS
CN 4-Piperidinepropanamide, 1-benzoyl-N-[(1R)-2-[(3S)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-98-0 CAPLUS
CN 4-Piperidinepropanamide, 1-benzoyl-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333952-99-1 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-00-7 CAPLUS
CN Acetamide, 2-[(1-benzoyl-4-piperidinyl)oxy]-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-01-8 CAPLUS
CN Benzamide, N-[cis-4-[[[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-02-9 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-03-0 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-04-1 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-05-2 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[(3S)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-06-3 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-07-4 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-08-5 CAPLUS
CN 4-Piperidinecarboxamide, 1-(4-chlorobenzoyl)-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-09-6 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[(tetrahydro-2H-pyran-4-yl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-10-9 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-11-0 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(2-methoxybenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-12-1 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(2-methylbenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-13-2 CAPLUS
CN 4-Piperidinecarboxamide, 1-(2-chlorobenzoyl)-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-14-3 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(1H-indol-2-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-15-4 CAPLUS
CN 4-Piperidinecarboxamide, 1-[4-(aminosulfonyl)benzoyl]-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-16-5 CAPLUS
CN 4-Piperidinecarboxamide, 1-[4-(acetylamino)benzoyl]-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-17-6 CAPLUS
CN 4-Piperidinecarboxamide, 1-[(5-acetyl-2-thienyl)carbonyl]-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-18-7 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[(1-methyl-1H-indol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-19-8 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-20-1 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(2-thienylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-21-2 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-22-3 CAPLUS
CN 4-Piperidinepropanamide, 1-(benzo[b]thien-2-ylcarbonyl)-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-23-4 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(2-methoxybenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-24-5 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[2-(methylsulfonyl)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-25-6 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(cyclopentylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-26-7 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[(4-chlorophenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-27-8 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[(3-chlorophenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-28-9 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[(2-chlorophenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-29-0 CAPLUS
CN 4-Piperidinepropanamide, 1-[4-(aminosulfonyl)benzoyl]-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-30-3 CAPLUS
CN 4-Piperidinepropanamide, 1-(2-chlorobenzoyl)-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-31-4 CAPLUS
CN 4-Piperidinepropanamide, 1-(3-chlorobenzoyl)-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-32-5 CAPLUS
CN 4-Piperidinepropanamide, 1-(4-chlorobenzoyl)-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-33-6 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[2-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-34-7 CAPLUS
CN 4-Piperidinepropanamide, 1-[3-(aminosulfonyl)-4-chlorobenzoyl]-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-35-8 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-36-9 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-37-0 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-38-1 CAPLUS
CN 4-Piperidinepropanamide, 1-[4-(acetylamino)benzoyl]-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-39-2 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(2-methylbenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-40-5 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(2-fluorobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-41-6 CAPLUS
CN 4-Piperidinepropanamide, 1-(2-acetylbenzoyl)-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-42-7 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(3-hydroxy-3-methyl-1-oxobutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-43-8 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[(2-fluorophenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-44-9 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[(2-methylphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-45-0 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[(2-methoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-46-1 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(cyclohexylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-47-2 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(2,2-dimethyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-48-3 CAPLUS
CN 4-Piperidinepropanamide, 1-[2-(acetyloxy)-2-methyl-1-oxopropyl]-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-49-4 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-50-7 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(phenylacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-51-8 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-52-9 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(1-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-53-0 CAPLUS
CN 4-Piperidinepropanamide, 1-acetyl-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-54-1 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[(2-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-55-2 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[(2-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-56-3 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-57-4 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-58-5 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-59-6 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-60-9 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-61-0 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-62-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-63-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-64-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-benzoyl-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-65-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(4-chlorophenyl)-4-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-66-5 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-67-6 CAPLUS
CN 1-Piperazinecarboxamide, 4-benzoyl-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-68-7 CAPLUS
CN 4-Piperidinecarboxamide, 1-benzoyl-N-[(1S)-2-[5-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-69-8 CAPLUS
CN 4-Piperidinepropanamide, 1-benzoyl-N-[(1S)-2-[5-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-70-1 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-5-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(2-hydroxybenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-71-2 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[5-(acetylamino)-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-72-3 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[5-(acetylamino)-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-benzoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-73-4 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[5-(acetylamino)-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-74-5 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[5-(acetylamino)-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-benzoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-75-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[5-(acetylamino)-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-76-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[5-(acetylamino)-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-77-8 CAPLUS
CN Acetamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-[[1-(trifluoroacetyl)-4-piperidinyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-78-9 CAPLUS
CN Benzamide, N-[[trans-4-[[[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-79-0 CAPLUS
CN 4-Piperidinecarboxamide, 1-benzoyl-N-[(1R)-2-[(3R)-6-chloro-3,4-dihydro-3-(1-pyrrolidinylmethyl)-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-80-3 CAPLUS
CN 4-Piperidinepropanamide, 1-benzoyl-N-[(1R)-2-[(3R)-6-chloro-3,4-dihydro-3-(1-pyrrolidinylmethyl)-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-81-4 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[(5-fluoro-1-methyl-1H-indol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-82-5 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[(2,3-dihydro-1H-inden-2-yl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-83-6 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(3-isoquinolinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-84-7 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(1H-indol-3-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-85-8 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(phenylacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-86-9 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-[(1-methyl-1H-indol-3-yl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-87-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(1H-indol-2-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-88-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-[(1-methyl-1H-indol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-89-2 CAPLUS
CN Acetamide, 2-[[1-(2-chlorobenzoyl)-4-piperidinyl]oxy]-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-90-5 CAPLUS
CN Acetamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-[[1-(2-methylbenzoyl)-4-piperidinyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-91-6 CAPLUS
CN Acetamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-[[1-(4-fluorobenzoyl)-4-piperidinyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-92-7 CAPLUS
CN Acetamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-[[1-(4-methylbenzoyl)-4-piperidinyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-93-8 CAPLUS
CN Acetamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-[[1-(phenylacetyl)-4-piperidinyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-94-9 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-95-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorobenzoyl)-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-96-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-[(2-fluorophenyl)methylene]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-97-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-98-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(phenylmethylene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333953-99-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-00-0 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-01-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-[(2-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-02-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3,4-dihydro-3-(1-pyrrolidinylmethyl)-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-03-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3,4-dihydro-3-(1-pyrrolidinylmethyl)-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-04-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3,4-dihydro-3-(1-pyrrolidinylmethyl)-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-05-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-06-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(3,4-dimethoxybenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-07-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-[(1-methyl-1H-indol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-08-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(4-chlorophenoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-09-9 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(4-methoxyphenoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-10-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(4-cyanophenoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-11-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-12-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-13-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-[(4-fluorophenyl)thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-14-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-[(4-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-15-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-[(4-chlorophenyl)thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-16-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-[(4-chlorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-17-9 CAPLUS
CN Acetamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-(4-piperidinyloxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-18-0 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-1-(2-hydroxy-2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-19-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **246866-77-3P 333954-62-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indolylpropanoyltetrahydroquinoline derivs. which inhibit binding of somatostatin receptors)
RN 246866-77-3 CAPLUS
CN 4-Piperidinecarboxamide, 1-benzoyl-N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333954-62-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I II

AB The title compds. [I; Ar = (un)substituted aromatic; X = CH2, S, SO, SO2, CO; Y = a spacer having a main chain of 2-5 atoms; n = 1-5; R1, R2 = H, lower alkyl; NR1R2 = (un)substituted nitrogen-containing heterocyclic ring; R1 or R2 together with -(CH2)n-N= form, bonded to a component atom of Ring B, a spiro-ring which may be substituted; Ring A = (un)substituted aromatic; Ring B = (un)substituted 4-7 membered nitrogen-containing non-aromatic ring, with a proviso that X = S, SO, SO2, CO when Ring A has as a substituent a group -NHCOR11 (wherein R11 = alkyl, alkoxyalkyl, alkylthioalkyl, etc.) or a group NHR12 (R12 = alkyl, cycloalkyl, cycloalkylalkyl, etc.)] or their salts which have an excellent somatostatin receptor binding inhibition action and are useful for preventing or treating glaucoma, acromegaly, diabetes, diabetic complications or tumor, and as analgesics, were prepared Thus, treatment of 1-[2-(R)-amino-3-(indol-3-yl)propanoyl]-3-(R,S)-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline (preparation described) with N,N'-disuccinimidyl carbonate and N-ethyldiisopropylamine in THF followed by the addition of solution of 1-phenylpiperazine and N-ethyldiisopropylamine in THF afforded II which showed IC50 of 0.009 μM and 0.0008 μM against SSTR2 and SSTR3 binding, resp.

ACCESSION NUMBER: 1999:672759 CAPLUS
DOCUMENT NUMBER: 131:286420
TITLE: Preparation of amine compounds as somatostatin receptor antagonists or agonists
INVENTOR(S): Suzuki, Nobuhiro; Kato, Kaneyoshi; Takekawa, Shiro; Terauchi, Jun; Endo, Satoshi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 257 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9952875	A1	19991021	WO 1999-JP1871	19990408

W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2327695	AA	19991021	CA 1999-2327695	19990408
AU 9952655	A1	19991101	AU 1999-52655	19990408
JP 2000226373	A2	20000815	JP 1999-100828	19990408
EP 1070054	A1	20010124	EP 1999-945683	19990408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6329389	B1	20011211	US 1999-424285	19991119

PRIORITY APPLN. INFO.:
JP 1998-96422 A 19980408
JP 1998-345328 A 19981204
WO 1999-JP1871 W 19990408

OTHER SOURCE(S): MARPAT 131:286420

IT **246866-60-4P 246866-61-5P 246866-85-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of amine compds. as somatostatin receptor antagonists or agonists)

RN 246866-60-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[3,4-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-61-5 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[[bis(phenylmethyl)amino]methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-85-3 CAPLUS
CN Carbamic acid, [[1,2,3,4-tetrahydro-1-[(2R)-3-(1H-indol-3-yl)-1-oxo-2-[[(4-phenyl-1-piperazinyl)carbonyl]amino]propyl]-3-quinolinyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **246866-10-4P 246866-13-7P 246866-15-9P**
246866-17-1P 246866-18-2P 246866-20-6P
246866-21-7P 246866-22-8P 246866-23-9P
246866-25-1P 246866-54-6P 246866-55-7P
246866-56-8P 246866-57-9P 246866-58-0P
246866-59-1P 246866-62-6P 246866-63-7P
246866-64-8P 246866-65-9P 246866-66-0P
246866-67-1P 246866-68-2P 246866-69-3P
246866-70-6P 246866-71-7P 246866-72-8P

246866-73-9P 246866-74-0P 246866-75-1P
246866-76-2P 246866-77-3P 246866-78-4P
246866-79-5P 246866-86-4P 246866-90-0P
246866-91-1P 246866-92-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amine compds. as somatostatin receptor antagonists or agonists)

RN 246866-10-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-13-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-15-9 CAPLUS
CN Spiro[naphthalene-2(1H),2'-piperidine]-1'-carboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-3,4-dihydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-17-1 CAPLUS
CN 1-Piperazinecarboxamide, 4-(2-chlorophenyl)-N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-18-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2-methoxyphenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-20-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2-pyridinyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-21-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2-pyrimidinyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-22-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-23-9 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-25-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-54-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3S)-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 246866-55-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3R)-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 246866-56-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R)-2-[(3S)-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 246866-57-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R)-2-[(3R)-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 246866-58-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3S)-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 246866-59-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3R)-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 246866-62-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1H-benzotriazol-1-yl)-N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-63-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-[5-(trifluoromethyl)-1H-benzotriazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-64-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2,3-dimethylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-65-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-66-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2,5-dimethylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-67-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(3-methoxyphenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-68-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-69-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[3,4-dihydro-3-[(methylamino)methyl]-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-70-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[3,4-dihydro-3-[[(phenylmethyl)amino]methyl]-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-71-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(1-naphthalenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-72-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-6-methoxy-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-73-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-6-methoxy-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-74-0 CAPLUS
CN 4-Piperidinecarboxamide, 1-benzoyl-N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-6-methoxy-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-75-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-76-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-77-3 CAPLUS
CN 4-Piperidinecarboxamide, 1-benzoyl-N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-78-4 CAPLUS
CN Benzenepropanamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-79-5 CAPLUS
CN Benzenebutanamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-86-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-(aminomethyl)-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-90-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-[7-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-91-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-[7-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246866-92-2 CAPLUS
CN 4-Piperidinecarboxamide, 1-benzoyl-N-[(1R)-2-[7-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 15:13:15 ON 29 MAR 2004)

     FILE 'REGISTRY' ENTERED AT 15:13:25 ON 29 MAR 2004
L1             STRUCTURE UPLOADED
L2          344 S L1 FUL

     FILE 'CAPLUS' ENTERED AT 15:14:01 ON 29 MAR 2004
L3            3 S L2

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      14.71     170.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -2.08      -2.08

STN INTERNATIONAL LOGOFF AT 15:14:35 ON 29 MAR 2004
```